KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenon Pharmaceuticals (XENE) EBT Margin: 2013-2025

Historic EBT Margin for Xenon Pharmaceuticals (XENE) over the last 9 years, with Mar 2025 value amounting to -861.60%.

  • Xenon Pharmaceuticals' EBT Margin was N/A to -861.60% in Q1 2025 from the same period last year, while for Mar 2025 it was -1,538.39%, marking a year-over-year change of. This contributed to the annual value of -1,327.70% for FY2022, which is 89982.00% down from last year.
  • Xenon Pharmaceuticals' EBT Margin amounted to -861.60% in Q1 2025, which was up 96.99% from -28,588.64% recorded in Q3 2022.
  • Xenon Pharmaceuticals' EBT Margin's 5-year high stood at -228.88% during Q1 2022, with a 5-year trough of -28,588.64% in Q3 2022.
  • Over the past 1 years, Xenon Pharmaceuticals' median EBT Margin value was -861.60% (recorded in 2025), while the average stood at -861.60%.
  • Within the past 5 years, the most significant YoY rise in Xenon Pharmaceuticals' EBT Margin was 13,440bps (2022), while the steepest drop was 2,824,086bps (2022).
  • Over the past 3 years, Xenon Pharmaceuticals' EBT Margin (Quarterly) stood at -671.13% in 2021, then plummeted by 2,824,086bps to -28,588.64% in 2022, then reached -861.60% in 2025.
  • Its EBT Margin stands at -861.60% for Q1 2025, versus -28,588.64% for Q3 2022 and -5,820.52% for Q2 2022.